Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
UROS CRISPR/Cas9 KO Plasmid (m): sc-423627
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- UROS CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the UROS genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: UROS Antibody (A-8): sc-365877
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UROS CRISPR/Cas9 KO Plasmid (m) | sc-423627 | 20 µg | $397.00 |
Overview
Uros encodes uroporphyrinogen III synthase (UROS), a cytosolic enzyme in the heme biosynthesis pathway that converts hydroxymethylbilane to uroporphyrinogen III, the physiological precursor for downstream porphyrin and heme production. This step is essential for maintaining cellular heme availability required for mitochondrial respiration, cytochrome function, and redox homeostasis. Disruption of UROS activity causes accumulation of non-physiologic porphyrin isomers and perturbs erythroid maturation and oxidative stress responses. In mouse models, Uros is commonly studied to interrogate porphyrin metabolism, erythropoiesis, and mechanisms linking heme pathway imbalance to tissue photosensitivity and anemia-associated phenotypes.
UROS CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Uros gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Uros together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Uros open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish UROS protein expression.
This CRISPR knockout system enables efficient generation of Uros-deficient cell models for investigation of UROS signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Uros exon(s) critical for UROS function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Uros genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by UROS CRISPR/Cas9 KO Plasmid (m) and UROS CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Uros locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by UROS HDR Plasmid (m) and UROS HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Uros homology arms to support homology-directed repair at defined Uros target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.